<DOC>
	<DOC>NCT02044328</DOC>
	<brief_summary>Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage IIA-IIIA adenocarcinoma patients with EGFR mutation. The primary endpoint is disease-free survival.</brief_summary>
	<brief_title>Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>The patients present with operable stage IIAIIIA (N01) lung adenocarcinoma with 19 or 21 exon mutation The patients have no history of anticancer therapies including chemotherapy, radiation therapy The patients' Eastern Cooperative Oncology Group scores are â‰¤ 01 The patients signed the written informed consent Patients with unresected tumor Wild EGFR type Allergic to the study drug Patients have severe noncancerous diseases Patients are undergoing current administration of anticancer therapies, or are attending some other clinical trials</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>